Submission is based on long-term Phase 3 data demonstrating 63 percent reduction in risk of relapse in adults with schizophrenia compared to placebo CAPLYTA ® is FDA approved to treat schizophrenia ...

The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profile CAPLYTA, if approved as ...

NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ...

Caplyta (lumateperone) is a prescription oral capsule used to treat schizophrenia and depression related to certain types of bipolar disorder. Caplyta may not be safe to take while pregnant or ...

Caplyta is a brand-name prescription medication containing the active ingredient lumateperone. Currently, no generic version of the medication is available. An important note about Caplyta for older ...

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. Johnson & Johnson won U.S. approval to sell the ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults, Johnson & Johnson announced. Lumateperone was previously ...

Add Yahoo as a preferred source to see more of our stories on Google. People gather next to a logo of Johnson & Johnson at the company’s booth at the 8th China International Import Expo (CIIE) in ...

Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration has further expanded the labeling for its atypical antipsychotic Caplyta to approve its use in adults with ...

BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ...